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Abstract
Depression during pregnancy and the postpartum period is a growing health problem, which affects up to 20% of women.
Currently, selective serotonin reuptake inhibitor (SSRIs) medications are commonly used for treatment of maternal
depression. Unfortunately, there is very little research on the long-term effect of maternal depression and perinatal SSRI
exposure on offspring development. Therefore, the aim of this study was to determine the role of exposure to fluoxetine
during development on affective-like behaviors and hippocampal neurogenesis in adolescent offspring in a rodent model of
maternal depression. To do this, gestationally stressed and non-stressed Sprague-Dawley rat dams were treated with either
fluoxetine (5 mg/kg/day) or vehicle beginning on postnatal day 1 (P1). Adolescent male and female offspring were divided
into 4 groups: 1) prenatal stress+fluoxetine exposure, 2) prenatal stress+vehicle, 3) fluoxetine exposure alone, and 4) vehicle
alone. Adolescent offspring were assessed for anxiety-like behavior using the Open Field Test and depressive-like behavior
using the Forced Swim Test. Brains were analyzed for endogenous markers of hippocampal neurogenesis via
immunohistochemistry. Results demonstrate that maternal fluoxetine exposure reverses the reduction in immobility
evident in prenatally stressed adolescent offspring. In addition, maternal fluoxetine exposure reverses the decrease in
hippocampal cell proliferation and neurogenesis in maternally stressed adolescent offspring. This research provides
important evidence on the long-term effect of fluoxetine exposure during development in a model of maternal adversity.
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Introduction
Depression during pregnancy and the postpartum period is a
growing health concern that affects up to 20% of women [1,2,3,4].
Maternal stress, depression and anxiety, can have long-term effects
on the physical and mental development of children [5,6,7]. For
example, antenatal maternal depression can lead to neurobehav-
ioral disturbances, such as impaired cognitive and social
developmental outcomes [6,7,8,9,10,11]. In rodent models, stress
during gestation, which results in depressive-like behavior in the
dam [12,13], models the clinical findings [11,14]. Several animal
studies have indicated that adult offspring of prenatally stressed
mothers show increases in affective-related behavior [14,15,16,17]
and decreased levels of hippocampal neurogenesis [18,19,20,21].
Given the development effect of exposure to maternal depression,
it is crucial to treat this disorder in order to improve maternal and
child outcomes.
Selective serotonin reuptake inhibitor (SSRIs) medications are
commonly used for the treatment of maternal depression [22].
Current estimates suggest that there is an increasing incidence of
SSRI use in mothers that ranges between 5–10% [23,24,25].
However, the effects of these medications on the developing child
have yet to be fully determined [5,26]. Recent clinical studies
report that neonates exposed to SSRI medications during
gestation, regardless of maternal mood state, have an increased
risk for low birth weight, younger gestational age, neurobehavioral
disturbances, and reduced heart rate variability [5,27,28]. Recent
evidence also demonstrates that prenatal exposure to SSRI-
medications may alter neurodevelopment as evidenced via
alterations in S100B levels [29]. In addition, perinatal exposure
to SSRI medications may have long term effects on mood in
children [30,31]. For example, children perinatally exposed to
maternal depression and SSRIs exhibit increased internalizing
behaviors at 3 years [31].
Preclinical data is beginning to show that exposure to SSRIs
during development significantly impacts offspring affective-like
behaviors and neural plasticity [5,26,32]. For example, SSRI
treatment, via intraperitoneal (i.p.) injection to offspring, during
the early postnatal period can result in increased depressive- and
anxiety-like behavior during adulthood [33,34,35]. Developmental
exposure to SSRIs may also influence neuroplasticity in the
hippocampus, through effects on brain derived neurotrophic
factor (BDNF) mRNA levels [34].
Although these studies point to a role for SSRIs in development,
it should be noted that in preclinical studies offspring are treated
with or exposed to SSRIs alone, and not in combination with
maternal depression. To date, very little research has looked at the
effect of maternal stress and SSRIs on offspring outcomes [36,37]
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and fluoxetine exposure [36]. This study demonstrated that
postnatal oral administration of the SSRI, fluoxetine, to pups
reverses the stress induced reduction in CA3 spine and synapse
density in juveniles and young adults [36]. In this study, SSRI
treatment alone, in the absence of maternal stress, had no affect on
spine density measures in the CA3 region of the hippocampus
[36]. Thus the actions of early exposure to SSRI medications may
be very different in the presence of maternal adversity. Therefore
to better translate these findings to the clinic, the effects of
maternal use of SSRI medications need to be investigated in
animal models of maternal adversity.
The aim of the present study was to investigate the
developmental effect of fluoxetine, a popular SSRI antidepressant
used during pregnancy, in a model of maternal adversity, on
anxiety and depression-related behavior and hippocampal neuro-
genesis in adolescent male and female offspring. Although research
has investigated the developmental impact of perinatal SSRI
exposure on offspring outcomes, little research has been done on
the neurodevelopmental effects of postnatal fluoxetine treatment
in an animal model of maternal depression. In addition, much less
research has looked at the long-term effects of developmental
SSRI exposure during adolescence, a time of vulnerability to stress
[38,39,40,41,42]. Our data shows that the exposure to fluoxetine
during development can reverse the effect of prenatal stress on
aspects of adolescent development. Knowledge of the effects of
maternal depression and antidepressant treatment during the
perinatal period is needed to ameliorate treatment and interven-
tion options, and thus improve neurodevelopmental outcomes.
Methods
Animals
Twenty-two adult female Sprague-Dawley rats (250–300 g;
Charles River Laboratories, France) were used in the present
study. Rats were kept under standard laboratory conditions in a
12h:12h light/dark schedule (lights on at 07:00 h) with ad libitum
access to rat chow (Sniff) and tap water. All experiments were
approved by the Animal Ethics Board of Maastricht University in
accordance with Dutch governmental regulations (approval IDs:
DEC 2008-157 and DEC 2008-158). All efforts were made to
minimize the pain and stress levels experienced by the animals.
On gestation day (GD) 15, dams were randomly assigned to
stress (n=12) or control groups (n=10). Dams in the stress group
were individually restrained three times a day for 45 min in
transparent plastic cylinders under bright light (between 8–10am,
12–2pm, 4–6pm) on GD15–20 and twice on GD21 as previously
described [43,44]. This time period during pregnancy is when
stress can result in postpartum depressive-like behavior in the dam
[12,13] and a period of stress that affects offspring outcomes
[17,45].
One day after birth (birth day=P0), litters were culled to 5
males and 5 females and dams (with offspring) were randomly
assigned to one of two treatment groups: fluoxetine (5 mg/kg/day)
or vehicle, for a total of four groups of dams: 1) Prenatal Stress +
Vehicle (PSV; n=5), 2) Prenatal Stress + Fluoxetine (PSF; n=7),
3) Control + Fluoxetine (CF; n=5), and 4) Control + Vehicle (CV;
n=5). A maximum of 2 male and 2 female offspring per litter were
used in the present experiment (n=9–11/sex/group). Offspring
litter was weighed on P21 and individual weights were taken once
between P29–31 and once between P39–42. For assessment of
hippocampal cell proliferation and neurogenesis, 5 animals per
group were used (1 male and 1 female from each litter). For a time
line of the experiment see Figure 1.
Fluoxetine treatment
Fluoxetine treatment was administered via osmotic minipumps
(Alzet Osmotic pumps, 2ML4) to the dam on P1. Fluoxetine and
its active metabolite, norfluoxetine, can pass to offspring through
lactation [46], therefore we used this mode of delivery to prevent
the stress of administration via injection, or oral gavage to the
offspring. In addition, rodent brain development during the early
postpartum period is analogous to human brain development
during the third trimester [47].
Implants were filled with either fluoxetine (Fagron, Belgium),
dissolved in vehicle (50% propylenediol in saline; 5 mg/kg/day),
or with vehicle as previously described [48]. Minipumps were
implanted subcutaneously in the dorsal region while the dams
were under mild isofluorene anesthesia on post-partum day 1 (P1).
Maternal care
Maternal care was assessed twice a day for 5 minutes from P2 to
P7 based on previous literature [49]. Scoring took place in the
morning (between 8:30 a.m. and 10:30 a.m.) and the afternoon
(between 13:30 p.m. and 15:30 p.m.) with at least 3 h between the
sessions. During each testing period the duration of the following
maternal behaviors was assessed: licking (licking/grooming;
licking/grooming/nursing), nursing (arched-back nursing, ‘‘blan-
ket’’ nursing, and passive nursing) and nest building. Data were
aggregated across days and were calculated as total percent time
spent in each behavior.
The Open Field Test (OFT)
The OFT was used to study anxiety-like behavior and
locomotor activity in adolescent offspring [50]. The open field
test consisted of a 100 cm6100 cm area divided into central and
peripheral areas with 40 cm high walls. For the test, a rat was
Figure 1. Timeline of experiment. Stress was administered between GD15-21. Fluoxetine treatment to the mother began 1 day after birth and
continued until weaning (P21). Between P32 and P39, offspring were subjected to behavioral tasks. At P42, offspring were sacrificed.
doi:10.1371/journal.pone.0024003.g001
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minutes. All animals were tested once between 9:30 a.m. and 2
p.m. (age P32–34). A video-tracking system (Anymaze, Stoelting)
was used to score the distance travelled, number of entries into the
central and peripheral areas, and total time spent in the central
and peripheral areas. The apparatus was cleaned with 70%
ethanol and dried between rats.
The Forced Swim Test (FST)
The forced swim test (FST) was used to assess depressive-like
behavior in the adolescent offspring as previously described
[51,52,53]. The apparatus consisted of a vertical cylindrical glass
tank (height 50 cm 6diameter 20 cm) filled to a depth of 20 cm
with tap water at 27 6 1uC. For the test, an animal was placed in a
cylindrical glass tank for 10 min. Offspring were tested on the
FST, between 9 a.m. and 1 p.m. (age P37–39). Using the Best
Collection System (Educational Consulting Inc.), behaviors scored
in the FST were (1) immobility – floating with the absence of any
movement and (2) struggling – quick movements of the forelimbs
such that the front paws break the surface of the water.
Immunohistochemistry (IHC)
A minimum of 2 days after the last behavioral test, offspring
were deeply anesthetised with an overdose of pentobarbital, and
decapitated. Half of the brain was used for IHC, the hippocampus
of the other half was used for further analysis not included in the
present study. Brains were post-fixed in 4% paraformaldehyde for
48 hours, cryoprotected in 30% sucrose/phosphate-buffered
saline solution for up to one week, frozen on dry ice and kept at
280uC. Brain tissue was sliced in 40 mm sections on a cryostat
(Leica). Tissue was stored in antifreeze solution and maintained at
215uC. The number of proliferating cells and immature neurons
were assessed in the dentate gyrus of the hippocampus using
endogenous markers, i.e. Ki67 for cell proliferation and double-
cortin (DCX) for immature neurons. Every 6
th section throughout
half the hippocampus was stained as previously described [54,55].
Sections were blocked with H2O2 and incubated overnight in
either rabbit anti-Ki67 (1:500; Vector Laboratories) or goat anti-
DCX (1:200; Santa Cruz). Sections were then incubated overnight
in biotinylated donkey anti-rabbit (1:500; Jackson ImmunoRe-
search, Suffolk, UK) or for 2 hours in biotinylated rabbit anti-goat
(1:500; Jackson ImmunoResearch) secondary antibody. Brain
sections were further processed by using the avidine-biotine
complex (ABC Elite kit; 1:1000; Vector laboratories). DAB (3,3-
diaminobenzidine; Sigma) was used as a substrate to obtain a color
reaction. Sections were mounted on gelatin-coated slides, dried
overnight, counterstained with Cresyl Violet acetate, dehydrated
and coverslipped with Permount (Fisher Scientific).
The number of Ki67 immunoreactive (-ir) cells and DCX-ir
cells were counted under 406 objective with oil as previously
described [54,55]. Cells were considered Ki67-ir if they were
intensely stained and exhibited medium round or oval cell bodies
(Figure 2A). Cells were considered DCX-ir if they exhibited
medium round or oval cell bodies and dendrites (Figure 2B). The
areas of the granule cell layer/subgranular zone (GCL/SGZ) and
hilus were measured using StereoInvestigator software (Micro-
BrightField, Williston, VT, USA) and estimates of GCL/SGZ and
hilus volumes were made using Cavalieri’s principle [56].
Statistical analyses
Analysis of variance tests (ANOVA) were done for maternal
behaviors with condition (prenatal stress/no stress) and treatment
(fluoxetine/vehicle) as independent factors. ANOVAs were done
on offspring weight gain, FST measures, OFT measures, Ki67-ir
and DCX-ir cell numbers with condition (prenatal stress/no
stress), treatment (fluoxetine/vehicle), and sex (male/female) as
independent factors. Pearson product moment correlations were
conducted between behaviors on the OFT (central entries, central
time, and central distance) and FST (struggling and floating), and
the total number of Ki67-ir and DCX-ir cells for all groups and
separately by treatment and condition. Any differences in age,
weight, time of testing or test order of the litter, were accounted
for, where appropriate, via an analysis of covariance. In cases
where clear sex differences were evident stratified analysis were




Stressed dams spent a significantly greater percentage of time
nest building compared to non-stressed dams, regardless of
fluoxetine treatment (main effect of treatment; F(1, 18)=10.66,
p#.004; Table 1). Independent of treatment condition, dams spent
a significantly greater percentage of time nursing offspring than
licking offspring (main effect of time; F(1, 18)=358.37, p#.00001;
Table 1).
Body weight change
CF and PSF offspring gained significantly less weight than CV
and PSV offspring, regardless of stress (main effect of treatment;
F(1,68)=15.33, p#.0002; Figure 3). Overall, male offspring
gained significantly more weight than female offspring (main
effect of sex; F(1,68)=16.71, p#.0001; Figure 3), even when
controlling for any age differences at the time of weighing.
The OFT
PSV male offspring made significantly fewer central entries
compared to CF and PSV female offspring (.007#p#.02:
condition6treatment6sex effect; F(1,69)=4.43, p#.04;
Figure 4A). There was also a significant main effect of sex with
male offspring making significantly fewer central entries compared
to female offspring (F(1,69)=4.14, p#.05). Further analysis by sex
revealed that PSV males made fewer central entries than CV, CF
and PSF adolescent males, however this did not reach significance
(p$0.09) and there were no significant effects of treatment or
condition in female adolescent offspring (p$0.14). There were no
other significant differences between groups in measures on the
OFT (.07#p#.90; Table 2).
The FST
PSV adolescent offspring spent significantly less time immobile
compared to CV and PSF offspring (.02#p#.04: condition6
treatment effect; F(1, 68)=7.17, p#.09, controlling for weight
differences; Figure 4B). There were no significant differences
between conditions, treatment or sex in amount of time spent
struggling in the FST and no other significant main effects or
interactions on measures of the FST (0.12#p#.90).
Ki67-ir cells
There were no significant differences between groups in the
volume of the GCL/SGZ and the hilus of the hippocampus
(p..07), therefore total number of Ki67-ir cell counts were used
for statistical analysis. Results demonstrate that PSV adolescent
offspring had significantly fewer Ki-67-ir cells in the GCL/SVZ
compared to all other groups (.0001#p#.01). CF adolescent
offspring had significantly more Ki67-ir cells in the GCL/SVZ
compared to PSV offspring (p#.0001), but significantly fewer
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(.002#p#.04; condition6fluoxetine6region (GCL, hilus) effect;
F(1, 32)=14.58, p#.0006; Figure 2C), regardless of sex. There
was also a significant interaction effect between stress and
fluoxetine (F(1,32)=18.1, p#.0002), a main effect of stress
(F(1,32)=4.18, p#.05) and a significant effect of region with
more Ki67-ir cells in the GCL/SVZ compared to the hilus
(F(1,32)=466.03, p#.0001). There were no significant correla-
tions between number of Ki67-ir in the GCL/SVZ and measures
on the OFT or FST and no other significant main effects of
interactions (0.07#p#.92).
DCX-ir cells
PSV adolescent offspring had significantly fewer number of
DCX-ir cells in the GCL/SGZ of the hippocampus compared to
all other groups (.009#p#.03, condition 6 treatment effect;
Table 1. Mean (6 SEM) percentage of time in maternal
behaviors.
CV CF PSV PSF
Licking (%) 11.0062.68 6.9261.68 10.5663.03 7.8261.89
Nursing (%) 71.565.84 79.1966.70 73.1464.06 72.9865.06
Nest building (%) 0.3660.12 0.2860.13 2.7860.89* 1.3260.51*
Stressed dams spent a significantly greater percentage of time nest building
compared to non-stressed dams, regardless of fluoxetine treatment (p#.004).
Regardless of treatment or condition, dams spent a significantly greater
percentage of time nursing offspring than licking offspring (p#.00001).
‘*’ denotes significantly different from CV and CF.
doi:10.1371/journal.pone.0024003.t001
Figure 2. Photomicrographs of representative A) Ki67-ir cells and B) DCX-ir cells in the GCL/SGZ and mean (± SEM) number of C)
Ki67-ir cells and D) DCX-ir cells in the GCL/SGZ. C) PSV adolescent offspring had significantly fewer Ki-67-ir cells in the GCL/SVZ compared to all
other groups (.0001#p#.01). CF adolescent offspring had significantly more Ki67-ir cells in the GCL/SVZ compared to PSV offspring (p#.0001), but
significantly fewer Ki67-ir cells in the GCL/SVZ compared to CV and PSF offspring (.002#p#.04), regardless of sex. D) PSV adolescent offspring had
significantly fewer number of DCX-ir cells in the GCL/SGZ of the hippocampus compared to all other groups (.006#p#.03), regardless of sex.
‘*’denotes significantly different from all other groups. (n=5/sex/group).
doi:10.1371/journal.pone.0024003.g002
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significant negative correlation between number of DCX-ir cells in
the GCL/SGZ and time spent in the centre of the OFT in PSV
offspring (r=2.83, p#.003) and a significant positive correlation
between number of DCX-ir cells in the GCL/SVZ and amount of
time spent struggling in the FST in CF offspring (r=.67, p#.03).
There were no other significant correlations between number of
DCX-ir cells in the GCL/SVZ and measures on the OFT or FST
and no other significant main effects of interactions (.07#p#.84).
Discussion
The results of the present study demonstrate that early exposure
to fluoxetine in combination with maternal stress has long-term
effects on body weight, depressive-like behavior, and hippocampal
neurogenesis in offspring. Our primary findings show that early
postnatal exposure to maternal fluoxetine reversed the decrease in
immobility in the FST, hippocampal cell proliferation and
hippocampal neurogenesis in maternally stressed adolescent
offspring. In addition, we found that fluoxetine exposure alone
significantly reduced hippocampal cell proliferation in comparison
to controls and maternally stressed offspring exposed to fluoxetine.
We did not find any differences in pup-directed maternal care with
fluoxetine treatment or maternal stress suggesting that our data
point to a developmental impact of fluoxetine, in the presence of
maternal adversity, on offspring outcomes.
Developmental exposure to fluoxetine reduces weight
gain in adolescent offspring
We found that postnatal fluoxetine exposure, regardless of
exposure to prenatal maternal stress, significantly decreased post-
weaning weight gain in adolescent male and female offspring.
Previous research showed that a high dose of in utero fluoxetine,
via drinking water to dams, resulted in a decrease of birth weight
and also a reduction in weight gain during the pre-weaning period
in rats [57]. Moreover, several studies have shown that postnatal
treatment of fluoxetine, via injection to offspring, leads to a loss of
body weight in adult mice and guinea pigs [34,58,59]. A reduction
in weight gain during the pre-weaning period may be a result of
the involvement of 5-HT in glucoregulation in the hypothalamus
[60] such that high levels of 5-HT, as a result of the blockade of 5-
HT reuptake by fluoxetine, may inhibit the ingestion of
carbohydrates and, as a consequence, lead to weight loss [61].
Prenatal stress and anxiety-like behavior in adolescent
offspring
In the present study we found that adolescent male offspring
had increased anxiety-like behaviors, as evident by fewer central
entries in the open field test, compared to adolescent female
offspring. We also report that prenatal stress increased anxiety-like
behavior in the adolescent male, but only significantly different in
comparison to prenatally stressed or fluoxetine-treated adolescent
females. Although further work is needed on the effect of prenatal
stress and maternal fluoxetine use on anxiety-like behavior of
offspring during adolescence, these data are in partial agreement
with work done in prenatally stressed adult offspring. For example,
previous research has shown an increase in anxiety-like behavior
in prenatally stressed adult male, but not female, offspring [62].
More recently work has also demonstrated an increase in anxiety-
like behavior in prenatally stressed male offspring, using a similar
maternal stress paradigm as in the present study [63].
We did not find an effect of developmental fluoxetine exposure
on anxiety-like behavior in adolescent offspring. Previous work has
also shown minimal effects of early fluoxetine exposure alone, via
i.p. injections to pups from postnatal day 4–21, on anxiety-like
behavior in adult male mice in the light-dark box or open field test
[34]. However, more recent work has shown that administration
of fluoxetine during gestation, to healthy non-stressed dams, results
in increased anxiety-like behavior in adult male rats, as measured
on the elevated plus maze [64]. Therefore, it seems likely that the
effect of early exposure to SSRIs, on anxiety-like behavior later in
life may depend on many factors which include the timing of the
SSRI exposure, the timing of the test, and the test used to assess
anxiety-like behavior.
Figure 3. Mean (± SEM) percentage in weight change from P29 to P42. CF and PSF offspring gained significantly less weight than CV and
PSV offspring, regardless of stress (p#.0002). Overall, male adolescent offspring gained significantly more weight than female offspring (p#.0001).
‘*’denotes CF and PSF significantly different from CV and PSV groups. ‘**’ denotes males significantly different from females. (n=9–11/sex/group).
doi:10.1371/journal.pone.0024003.g003
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like behaviors and measures of hippocampal neurogenesis in the
adolescent rats. Previous work has demonstrated that hippo-
campal neurogenesis is associated with anxiety-like behavior in
adulthood; Revest et al (2009) demonstrated that transgenic
mice with decreased levels of hippocampal neurogenesis had
increased anxiety-like behavior [65]. However, more research is
needed to determine the role of hippocampal neurogenesis in
anxiety-like behavior during development. It should also be
noted that the relationship between hippocampal neurogenesis
and anxiety-like behavior in adolescent rats may significantly
vary compared to that of transgenic adult mice as there are well
known strain and species differences in hippocampal neurogen-
esis [66].
Figure 4. Mean (± SEM) A) number of central entries (OFT) and B) time spent immobile (FST). A) PSV male offspring made significantly
fewer central entries compared to CF and PSV female offspring (.007#p#.02). There was also a significant main effect of sex with male offspring
making significantly fewer central entries compared to female offspring (p#.05). Further analysis by sex revealed that PSV males made fewer central
entries than CV, CF and PSF adolescent males, however this did not reach significance (p$0.09) and there were no significant effect of treatment or
condition in female adolescent offspring (p$0.14). B) PSV adolescent offspring spent significantly less time immobile compared to CV and PSF
offspring (.02#p#.04). (n=9–11/sex/group).
doi:10.1371/journal.pone.0024003.g004
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effects of prenatal stress on immobility in adolescent
offspring
In the present study we found that developmental fluoxetine
exposure to prenatally stressed offspring reversed the decrease in
immobility in the FST seen in adolescent offspring exposed to
prenatal stress alone, while developmental fluoxetine exposure
alone had no significant effect on immobility in adolescent
offspring. Previous work on the effects of postnatal SSRI treatment
on depressive-like behavior in offspring has shown that i.p.
injection of SSRIs to offspring during development, in the absence
of maternal stress, leads to increased immobility in the FST during
adulthood [33,67]. Others have shown that oral fluoxetine
administration to the dam during pregnancy and lactation
increases immobility in the forced swim test during adolescence
(P30) and adulthood (P70) in female mouse offspring [68].
Discrepancies between our findings and others may be due to
the timing and dose of fluoxetine administration, the species tested,
and when, after weaning, animals were tested. For example,
Lisboa et al (2007) found that fluoxetine exposure (7.5 mg/kg), via
oral gavage, to mouse dams during pregnancy and lactation
resulted in increased depressive-like behavior in female mouse
offspring during adolescence, where as we administered fluoxetine
(5 mg/kg) to rat dams during lactation only and tested rat
offspring during adolescence. Therefore, the developmental
impact of SSRIs may also depend on when during development
the exposure occurred. It is also possible that other tests of
depressive-like behavior, such as the sucrose preference test, may
provide more insight in to the effects of stress and/or SSRIs on
offspring behavior.
Although, the exact mechanisms by which fluoxetine counter-
acts the decrease in immobility in prenatally stressed adolescent
offspring is not known, considerable evidence suggests that
prenatal maternal stress programs the hypothalamic-pituitary-
adrenal (HPA) axis as well as behavior, and that plasticity of the
developing monoamine system in the brain underlies, in part,
these changes [11,69]. Furthermore, prenatal exposure to
fluoxetine can alter HPA function [5,36,70], and thus may act
to ‘regulate’ physiological systems impacted by early exposure to
maternal adversity.
Developmental exposure to fluoxetine increases
hippocampal neurogenesis in prenatally stressed
adolescent offspring
In the present study postnatal fluoxetine exposure to maternally
stressed offspring reversed the decrease in hippocampal neuro-
genesis evident after prenatal stress. In addition, postnatal
fluoxetine exposure alone decreased hippocampal cell proliferation
but had no effect on hippocampal neurogenesis. During
adulthood, chronic fluoxetine treatment can significantly upregu-
late hippocampal neurogenesis [71,72]. However, our data
suggests that developmental exposure to fluoxetine reverses the
decrease in hippocampal cell proliferation and hippocampal
neurogenesis in prenatally stressed offspring and returns the levels
of hippocampal neurogenesis back to those of control animals.
Interestingly, these data point to a long-term impact of
developmental exposure to fluoxetine on hippocampal neurogen-
esis which are dependent on exposure to maternal adversity.
Whether these changes in hippocampal cell proliferation and
production of immature neurons impact hippocampal circuitry
and behavioral correlates remains to be determined. Further work
is also needed to investigate the persistence of the effects of
maternal adversity and developmental exposure to fluoxetine on
hippocampal neurogenesis in adult offspring.
The mechanism behind the effects of SSRI exposure on the
developing hippocampus has yet to be determined, but develop-
mental exposure to SSRIs have been reported to affect the
developing serotonergic system [73,74], and BDNF levels in the
hippocampus [34]. For example, postnatal citalopram treatment,
via subcutaneous injections to the pups (P8–21) can lead to a
decrease in the serotonin transporter levels in the hippocampus of
rat offspring [73]. In addition, postnatal treatment with SSRIs, via
i.p. injections to the offspring, can lead to upregulation of BDNF
mRNA in the hippocampus [34]. Thus exposure to SSRIs during
development may act to alter hippocampal neurogenesis through
its actions on many systems of the developing brain.
Our data also demonstrates that the action of fluoxetine on the
hippocampal neurogenesis varies in the presence of maternal
stress. Although most research to date has investigated the
developmental impact of SSRIs in offspring of healthy mothers,
one study has shown that early treatment with fluoxetine may act
to ‘correct’ the effect of maternal stress on neuron morphology
[36]. In this work Ishiwata et al (2005) demonstrated that postnatal
SSRI administration, via oral administration of fluoxetine to pups,
reverses the prenatal stress induced reduction in CA3 spine density
at 3 and 9 weeks of age but SSRI treatment alone, in the absence
of maternal stress, had no long-term effect on spine density
measures in the CA3 region of the hippocampus of offspring [36].
As mentioned previously, it is likely that developmental exposure
to fluoxetine in offspring exposed to maternal adversity, may act to
regulate the HPA axis and thus ‘normalize’ the effect of
glucocorticoids on hippocampal plasticity in prenatally stressed
Table 2. Mean (6 SEM) total distance and time in the centre of the OFT and percent time spent struggling during the FST.
Female offspring Male Offspring
CV CF PSV PSF CV CF PSV PSF
OFT:
Total distance (m) 24.4661.84 27.4861.71 26.9362.15 21.8562.63 24.4162.71 22.3261.99 22.8061.76 24.4161.77
Central distance (m) 2.366.56 3.476.65 2.866.39 1.796.36 1.876.34 2.496.39 1.796.18 2.206.53
Centre time (sec) 21.1666.27 20.4463.43 15.7461.83 15.0462.68 10.9362.06 16.6963.71 13.4661.49 16.3764.60
FST:
Struggling (sec) 52.30610.2 47.0967.82 57.63613.45 53.9067.84 53.54611.77 30.3665.38 61.66613.83 47.25612.38
There were no significant differences between treatments, condition, or sex in total or central distance travelled on the OFT or amount of time spent in the centre of the
OFT. There were also no significant differences between treatment, conditions, or sex in amount of time spent struggling in the FST (0.12#p#.90).
doi:10.1371/journal.pone.0024003.t002
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fluoxetine action on the developing brain in response to maternal
adversity.
Conclusions
A growing number of children are exposed to SSRI medications
during perinatal development [5], yet our knowledge of the long-
term impact of this drug exposure is limited. Findings from our
work show that developmental exposure to maternal fluoxetine, in
combination with exposure to prenatal maternal stress, reverses
the effects of prenatal stress on depressive-like behavior and
hippocampal neurogenesis in adolescent offspring. Thus, there
may be a potential beneficial role of developmental exposure to
fluoxetine in the presence of maternal adversity. However, before
conclusions can be made much more work is needed not only in
models of maternal adversity, but using other popular SSRIs,
serotonin-norepinephrine reuptake inhibitors (SNRIs) and psy-
chotropic medications being used to treat mood disorders during
pregnancy and postpartum [32].
In conclusion, further preclinical work is needed to understand
the long-term implications of developmental exposure to SSRIs
and other antidepressant medications in the presence of maternal
adversity before conclusions can be made about the use of
antidepressant medications to treat maternal depression during the
perinatal period.
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